7116-44-1

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 3-(4-AMINOPHENYL)PROPANOATE is used as an intermediate in the synthesis of various medications, particularly for the development of analgesics and anti-inflammatory drugs. Its role in the production of these medications is crucial, as it aids in the creation of effective pain relief and inflammation management options for consumers.
Used in Organic Synthesis:
In the field of organic synthesis, ETHYL 3-(4-AMINOPHENYL)PROPANOATE is utilized for the preparation of a range of organic compounds. Its versatility in chemical reactions makes it a valuable component in the synthesis of various organic molecules, contributing to the advancement of chemical research and development.
Used in Research Laboratories:
ETHYL 3-(4-AMINOPHENYL)PROPANOATE is also employed in research laboratories for conducting experiments and developing new organic compounds. Its properties and reactivity make it an essential tool for scientists and researchers working in the field of organic chemistry, enabling them to explore new avenues and create innovative chemical solutions.

InChI:InChI=1/C11H15NO2/c1-2-14-11(13)8-5-9-3-6-10(12)7-4-9/h3-4,6-7H,2,5,8,12H2,1H3

Upstream product

• 953-26-4 ethyl 4-nitrocinnamate 
• 5048-82-8 ethyl 4-aminocinnamate 
• 24393-61-1 ethyl (E)-3-(4-nitrophenyl)-2-propenoate 
• 140-88-5 ethyl acrylate 
• 586-78-7 para-nitrophenyl bromide 
• 5048-82-8 (E)-ethyl 3-(4-aminophenyl)acrylate 
• 555-16-8 4-nitrobenzaldehdye 
• 1099-45-2 ethyl (triphenylphosphoranylidene)acetate 
• 7116-34-9 ethyl 3-(4-nitrophenyl)propanoate 
• 16642-79-8 3-(4-nitrophenyl)propionic acid 
• 51507-21-2 ethyl (2Z)-3-(4-nitrophenyl)prop-2-enoate 
• 7440-44-0 pyrographite 
• 64-17-5 ethanol 
• 2393-17-1 3-(4-aminophenyl)propionic acid 

Downstream Products

• 124673-89-8 3-{4-[bis-(2-hydroxy-ethyl)-amino]-phenyl}-propionic acid ethyl ester 
• 406725-56-2 3-(4-benzamidophenyl)propanoic acid 
• 158425-29-7 ethyl 3-<4-(trifluoromethanesulfonamido)phenyl>propionate 
• 158425-22-0 ethyl 3-(4-methanesulfonamidophenyl)propionate 
• 81265-77-2 4-(4-Indazol-2-yl-phenyl)-butan-2-one 
• 81265-72-7 3-(4-Indazol-2-yl-phenyl)-propionic acid 
• 198896-22-9 ethyl 3-(4-tert-butoxycarbonylaminophenyl)propionate 
• 785779-22-8 ethyl 3-(4-(((benzyloxy)carbonyl)amino)phenyl)propanoate 
• 14572-92-0 3-(4-aminophenyl)propan-1-ol 

Relevant academic research and scientific papers

SAR Studies of Indole-5-propanoic Acid Derivatives to Develop Novel GPR40 Agonists

G-protein coupled receptor 40 (GPR40) has been considered to be an attractive drug target for the treatment of type 2 diabetes because of its role in free fatty acids-mediated enhancement of glucose-stimulated insulin secretion (GSIS) from pancreatic β-cells. A series of indole-5-propanoic acid compounds were synthesized, and their GPR40 agonistic activities were evaluated by nuclear factor of activated T-cells reporter assay and GSIS assay in the MIN-6 insulinoma cells. Three compounds, 8h (EC50 = 58.6 nM), 8i (EC50 = 37.8 nM), and 8o (EC50 = 9.4 nM), were identified as potent GPR40 agonists with good GSIS effects.

Structure-activity relationship and mechanistic studies for a series of cinnamyl hydroxamate histone deacetylase inhibitors

Histone deacetylases (HDACs) are a family of enzymes that modulate the acetylation status histones and non-histone proteins. Histone deacetylase inhibitors (HDACis) have emerged as an alternative therapeutic approach for the treatment of several malignanc

Reduction of Electron-Deficient Alkenes Enabled by a Photoinduced Hydrogen Atom Transfer

Direct hydrogen atom transfer from a photoredox-generated Hantzsch ester radical cation to electron-deficient alkenes has enabled the development of an efficient formal hydrogenation under mild, operationally simple conditions. The HAT-driven mechanism is supported by experimental and computational studies. The reaction is applied to a variety of cinnamate derivatives and related structures, irrespective of the presence of electron-donating or electron-withdrawing substituents in the aromatic ring and with good functional group compatibility. (Figure presented.).

A mild and selective Cu(II) salts-catalyzed reduction of nitro, azo, azoxy, N-aryl hydroxylamine, nitroso, acid halide, ester, and azide compounds using hydrogen surrogacy of sodium borohydride

The first mild, in situ, single-pot, high-yielding well-screened copper (II) salt-based catalyst system utilizing the hydrogen surrogacy of sodium borohydride for selective hydrogenation of a broad range of nitro substrates into the corresponding amine under habitancy of water or methanol like green solvents have been described. Moreover, this catalytic system can also activate various functional groups for hydride reduction within prompted time, with low catalyst-loading, without any requirement of high pressure or molecular hydrogen supply. Notably, this system explores a great potential to substitute expensive traditional hydrogenation methodologies and thus offers a greener and simple hydrogenative strategy in the field of organic synthesis.

One-Pot, Tandem Wittig Hydrogenation: Formal C(sp3)-C(sp3) Bond Formation with Extensive Scope

A one-pot, tandem Wittig hydrogenation of aldehydes with stabilized ylides is reported, representing a formal C(sp3)-C(sp3) bond construction. The tandem reaction operates under mild conditions, is high yielding, and is broad in scope. Chemoselectivity for olefin reduction is observed, and the methodology is demonstrated in the synthesis of lapatinib analogues and a formal synthesis of (±)-cuspareine. Early insights suggest that the chemoselectivity observed in the reduction step is due to partial poisoning of the catalyst, after step one, thus adding to the power of the one-pot procedure.

Improving the Potency of Cancer Immunotherapy by Dual Targeting of IDO1 and DNA

Herein we report the first exploration of a dual-targeting drug design strategy to improve the efficacy of small-molecule cancer immunotherapy. New hybrids of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors and DNA alkylating nitrogen mustards that respectively target IDO1 and DNA were rationally designed. As the first-in-class examples of such molecules, they were found to exhibit significantly enhanced anticancer activity in vitro and in vivo with low toxicity. This proof-of-concept study has established a critical step toward the development of a novel and effective immunotherapy for the treatment of cancers.

Novel compounds having GPR40 agonistic activity and use thereof

The present invention relates to a novel compound having GPR40 agonistic activities and a pharmaceutical composition for preventing or treating diabetes comprising the same as an active ingredient. According to the present invention, the novel compound or

Synthesis method of quinoline derivative

The invention discloses a preparation method of 3-(2-methylquinoline-6-yl)propionamide. A target product is obtained by taking ethyl 4-aminocinnamate as a starting raw material through reduction, ring closure and amidation. The compound is an important pharmaceutical intermediate.

Palladium on Polydopamine: Its True Potential in Catalytic Transfer Hydrogenations and Heck Coupling Reactions

The application of Pd–polydopamine and magnetic Fe3O4@Pd–polydopamine catalysts in catalytic transfer hydrogenation reactions and the Heck arylation is reported. The reduction of a wide range of aromatic nitro-compounds bearing both electron-donating and -withdrawing substituents to the corresponding anilines could be efficiently performed, although the reduction of carbonyl compounds was found to be less general. In the latter case, only aromatic ketones could be reduced to the corresponding alcohols, whereas aldehyde substrates were unaffected, which may be owing to their reaction with the catalyst support leading to catalyst deactivation. By using magnetic Fe3O4@Pd–polydopamine system, facilitated catalyst recovery and reuse for five consecutive cycles without considerable loss of activity in nitro-group reduction. The efficiency of the catalyst in Heck reactions was comparable to that in transfer hydrogenation, however, no catalytic activity was observed upon reuse in this case, likely as a result of metal leaching. We also explored tandem Heck reaction/catalytic transfer hydrogenation sequences, however, the two reactions showed limited compatibility under the applied conditions.

Sustainable and Scalable Fe/ppm Pd Nanoparticle Nitro Group Reductions in Water at Room Temperature

An operationally simple and general process for the safe and selective reduction of nitro groups utilizing ppm Pd supported on Fe nanomaterials in aqueous solution of designer surfactant TPGS-750-M has been developed and successfully carried out at a 100 mmol scale. Preferred use of KBH4 as the hydride source, at ambient temperature and pressure, lends this process suitable for a standard reaction vessel alleviating the need for specialized hydrogenation equipment. Calorimetry data parallel those expected for a classical nitro group reduction when measuring the heat of reaction (-896 to -850 kJ/mol).